Evidence map›Paper›PMID 28392174›Full record

ArticleMolecular cell2017

eIF5A Functions Globally in Translation Elongation and Termination.

Anthony P Schuller, Colin Chih-Chien Wu, Thomas E Dever, Allen R Buskirk, Rachel Green

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cell, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 305 papers.

0numbers the graph read from it
0cells of the map it votes in
305citing papers in PubMed
18.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

305 citing papers in PubMed, 508 citations in OpenAlex.

  1. Article
  2. Review
  3. Translation factors that keep the ribosome Pro-active.Microbiology and molecular biology reviews : MMBR · 2026
    Review
  4. eIF5A and polyamines restrict mRNA levels in response to ribosome stalls.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  5. Article
  6. eLife · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. eIF5A coordinates the transcription and translation of its target genes.Cellular and molecular life sciences : CMLS · 2026
    Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

245 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Anthony P SchullerDepartment of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Colin Chih-Chien WuDepartment of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Thomas E DeverEunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA.
Allen R BuskirkDepartment of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Rachel GreenDepartment of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Electronic address: ragreen@jhmi.edu.
Johns Hopkins Medicine · USEunice Kennedy Shriver National Institute of Child Health and Human Development · USJohns Hopkins University · US

Funding

Mechanism and Regulation of Eukaryotic Protein SynthesisZIAHD001010 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI DEVER, THOMAS E · 2009 to 2025
$29.4M
Molecular mechanisms of ribosome pausing and the cellular responseR37GM059425 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI GREEN, RACHEL · 2014 to 2023
$3.5M
The role played by the RNAs and tRNAs in translationR01GM059425 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI GREEN, RACHEL · 1999 to 2013
$3.4M
The Mechanism of Pausing and Restarting Translation in BacteriaR01GM110113 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI BUSKIRK, ALLEN ROWDON · 2014 to 2017
$1.2M
NIGMS NIH HHS R01 GM059425NIGMS NIH HHS R01 GM110113NIGMS NIH HHS R37 GM059425
6 · The paper itself

Abstract

The eukaryotic translation factor eIF5A, originally identified as an initiation factor, was later shown to promote translation elongation of iterated proline sequences. Using a combination of ribosome profiling and in vitro biochemistry, we report a much broader role for eIF5A in elongation and uncover a critical function for eIF5A in termination. Ribosome profiling of an eIF5A-depleted strain reveals a global elongation defect, with abundant ribosomes stalling at many sequences, not limited to proline stretches. Our data also show ribosome accumulation at stop codons and in the 3' UTR, suggesting a global defect in termination in the absence of eIF5A. Using an in vitro reconstituted translation system, we find that eIF5A strongly promotes the translation of the stalling sequences identified by profiling and increases the rate of peptidyl-tRNA hydrolysis more than 17-fold. We conclude that eIF5A functions broadly in elongation and termination, rationalizing its high cellular abundance and essential nature.

Indexed as

Peptide Chain Elongation, TranslationalPeptide Chain Termination, Translational3' Untranslated RegionsAmino Acid MotifsCodon, TerminatorEukaryotic Translation Initiation Factor 5AGene Expression ProfilingHydrolysisKineticsPeptide Initiation FactorsPeptidesPeptide Termination FactorsPeptidyl TransferasesRibosomesRNA-Binding ProteinsRNA, Fungal3' Untranslated RegionsCodon, TerminatorEukaryotic Translation Initiation Factor 5APeptide Initiation FactorsPeptidesPeptide Termination FactorsPeptidyl TransferasespolyprolineRNA-Binding ProteinsRNA, FungalRNA, Transfer, Amino AcylSaccharomyces cerevisiae ProteinsSUP45 protein, S cerevisiaetRNA, peptidyl-biochemistryeIF5Aribosome profilingtranslation elongationtranslation termination

Identifiers

PMID28392174
PMCPMC5414311
OpenAlexW2604467178

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.